Feasibility of detecting hypoxia in experimental mouse tumours with F-18-fluorinated tracers and positron emission tomography - A study evaluating [F-18]fluoromisonidazole and [F-18]fluoro-2-deoxy-D-glucose

Citation
L. Bentzen et al., Feasibility of detecting hypoxia in experimental mouse tumours with F-18-fluorinated tracers and positron emission tomography - A study evaluating [F-18]fluoromisonidazole and [F-18]fluoro-2-deoxy-D-glucose, ACTA ONCOL, 39(5), 2000, pp. 629-637
Citations number
32
Categorie Soggetti
Onconogenesis & Cancer Research
Journal title
ACTA ONCOLOGICA
ISSN journal
0284186X → ACNP
Volume
39
Issue
5
Year of publication
2000
Pages
629 - 637
Database
ISI
SICI code
0284-186X(2000)39:5<629:FODHIE>2.0.ZU;2-G
Abstract
The study was designed to investigate the binding of [F-18]Fluoromisonidazo le ([F-18]FMISO) and [F-18]Fluoro-2-deoxy-D-glucose ([F-18]FDG) in a C3H mo use mammary carcinoma. Non-anaesthetized tumour-bearing animals breathing e ither normal air or carbogen (to reduce tumour hypoxia) were examined by PE T after tracer injection. Tumours were identified by radioactive labelling and methods of defining regions of interest (ROI) in the rumours were inves tigated. Reference tissue was selected elsewhere in the mice and the ratio between mean radioactivity in tumour and reference tissue was compared. The results showed a correlation between the methods of identifying ROIs and a significantly lower tumour to reference tissue ratio for carbogen-treated mice compared with controls when using [F-18]FMISO. Only one of the methods showed a significant difference in the tumour labelling between treatment groups using [F-18]FDG. The study supports the contention that [F-18]FMISO may be able to identify hypoxia in tumours, whereas a similar role for [F-1 8]FDG is more doubtful.